US law permits secondary use of de-identified clinical data for research purposes without a patient’s knowledge or consent. But biospecimens, and genomic sequence data derived from them, are increasingly linked to clinical data in the era of genomic and precision medicine. What are the risks involved, and where should the limits lie?
Join Dr. Tenenbaum for dinner and discussion at this Science and Society Dinner Dialogue. This event is free to attend and transportation is available if needed. Selected attendees will be notified via email several days in advance of the dinner with details regarding meeting location.